Compare ARLO & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARLO | IMCR |
|---|---|---|
| Founded | 2018 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2018 | 2016 |
| Metric | ARLO | IMCR |
|---|---|---|
| Price | $12.57 | $36.86 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | $24.00 | ★ $66.33 |
| AVG Volume (30 Days) | ★ 1.3M | 390.2K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 145.16 | 30.39 |
| EPS | 0.16 | ★ 0.23 |
| Revenue | N/A | ★ $249,428,000.00 |
| Revenue This Year | $9.29 | $14.57 |
| Revenue Next Year | $8.82 | $8.21 |
| P/E Ratio | ★ $82.19 | $157.91 |
| Revenue Growth | N/A | ★ 43.05 |
| 52 Week Low | $11.05 | $27.56 |
| 52 Week High | $19.94 | $40.71 |
| Indicator | ARLO | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 36.99 | 61.32 |
| Support Level | $12.19 | $35.46 |
| Resistance Level | $14.00 | $37.38 |
| Average True Range (ATR) | 0.46 | 1.15 |
| MACD | -0.15 | -0.00 |
| Stochastic Oscillator | 8.33 | 83.19 |
Arlo Technologies Inc is engaged in the provision of security and video monitoring solutions for homes and businesses. Its cloud-based platform provides users with visibility, insight, and a powerful means to help protect and connect in real-time with the people and things that matter, from any location with a Wi-Fi or cellular connection. The company offers subscription services such as Arlo Secure, Arlo Total Security, and Arlo Safe, and several categories of smart security devices, including smart Wi-Fi and LTE-enabled cameras, video doorbells, floodlight cameras, and home security systems. Geographically, the company generates a majority of its revenue from the United States, followed by Spain, Sweden, and other countries.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.